Technology
Health
Pharmaceutical

VIVUS

$3.82
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-1.03%) Today
-$0.04 (-1.04%) After Hours

Why Robinhood?

You can buy or sell VIVUS and other stocks, options, ETFs, and crypto commission-free!

About

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Read More Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.

Employees
57
Headquarters
Campbell, California
Founded
1991
Market Cap
41.06M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
97.70K
High Today
$3.94
Low Today
$3.86
Open Price
$3.93
Volume
2.34K
52 Week High
$9.10
52 Week Low
$2.15

Collections

Technology
Health
Pharmaceutical
US
North America

News

Yahoo FinanceMay 6

VVUS: New Ideas for Established Portfolio

By John Vandermosten, CFA NASDAQ:VVUS READ THE FULL VVUS RESEARCH REPORT We are initiating coverage of VIVUS, Inc. (VVUS) with a $10.00 price target based on our revenue forecasts for approved products. In addition to a portfolio of weight loss, exocrine pancreatic insufficiency (EPI) and erectile dysfunction (ED) solutions, Vivus maintains a development program for pulmonary arterial hypertension (PAH). Existing product Qsymia and recently acquired product Pancreaze are expected to be the main rev...

55
NasdaqApr 30

VIVUS Reports First Quarter 2019 Financial Results

10
Seeking AlphaApr 30

VIVUS, Inc. (VVUS) CEO John Amos on Q1 2019 Results - Earnings Call Transcript

VIVUS, Inc. (NASDAQ:VVUS) Q1 2019 Earnings Conference Call April 30, 2019 4:30 PM ET Company Participants David Carey - Managing Director, Investor Relations, Lazar Partners John Amos - Chief Executive Officer Mark Oki - Chief Financial Officer Santosh Varghese - Chief Medical Officer Conference Call Participants John Vandermosten - Zacks Small Capital Research Operator Good afternoon, and welcome to the VIVUS First Quarter 2019 Financial Results Conference Call. Today's call is being recorded. Fo...

22

Earnings

-$1.17
-$0.80
-$0.43
-$0.06
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.